Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2009 by Shahid Beheshti Medical University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Shahid Beheshti Medical University
ClinicalTrials.gov Identifier:
NCT00999791
First received: July 7, 2009
Last updated: May 3, 2010
Last verified: October 2009

July 7, 2009
May 3, 2010
July 2009
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00999791 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema
Not Provided

Diffuse Macular Edema is the main cause of visual disorders in diabetic patients.

Diclofenac is a cheap drug available in most of treatment centers.in animal studies the safe dosage is identified that can be used in diffuse diabetic macular edema for treatment. in this study, we are going to compare the effect of intra vitreal injection of Diclofenac and Bevacizumab in primary treatment of diffuse diabetic macular edema.

Diffuse Macular Edema is the main cause of visual disorders in diabetic patients.

Diclofenac is a cheap drug available in most of treatment centers.in animal studies the safe dosage is identified that can be used in diffuse diabetic macular edema for treatment. in this study, we are going to compare the effect of intra vitreal injection of Diclofenac and Bevacizumab in primary treatment of diffuse diabetic macular edema.

Interventional
Phase 1
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Diffuse Diabetic Macular Edema
  • Drug: Bevacizumab
  • Drug: Diclofenac
  • Active Comparator: Avastin
    Intervention: Drug: Bevacizumab
  • Active Comparator: Diclofenac
    Intervention: Drug: Diclofenac
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • patients with clinically significant macular edema and diffuse macular edema

Exclusion Criteria:

  • any history of focal photocoagulation
  • any prior intra ocular injection
  • history of glaucoma with high pressure
  • history of ophthalmic surgery
  • high rish PDR
  • active PDR
Both
Not Provided
Not Provided
Contact: Masoud Soheilian, MD +982122585952 labbafi@hotmail.com
Iran, Islamic Republic of
 
NCT00999791
8818
Yes
Not Provided
Shahid Beheshti Medical University
Not Provided
Not Provided
Shahid Beheshti Medical University
October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP